{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T16:16:42Z","timestamp":1649002602574},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,4,25]],"date-time":"2008-04-25T00:00:00Z","timestamp":1209081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00393-008-0282-9","type":"journal-article","created":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T14:20:31Z","timestamp":1208960431000},"page":"211-219","source":"Crossref","is-referenced-by-count":5,"title":["Prim\u00e4res und sekund\u00e4res Raynaud-Ph\u00e4nomen"],"prefix":"10.1007","volume":"67","author":[{"given":"J.H.W.","family":"Distler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,25]]},"reference":[{"key":"282_CR1","unstructured":"Raynaud M (1988) Local asphyxia and symmetrical gangrene of the extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874. Translated by Barlow. New Sydenham Society, London"},{"key":"282_CR2","unstructured":"Lewis T (1929) Experiments relating to the peripherial mechanism involved in the vasospastic arrest of the circulation in the fingers, a variety of Raynaud\u2019s disease. Heart 15"},{"key":"282_CR3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00393-006-0068-x","volume":"65","author":"Distler","year":"2006","unstructured":"Distler M, Distler J, Ciurea A et al. (2006) Evidenzbasierte Therapie des Raynaud-Syndroms. Z Rheumatol 65: 285\u2013289","journal-title":"Z Rheumatol"},{"key":"282_CR4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00105-006-1192-x","volume":"57","author":"Sunderk\u00f6tter","year":"2006","unstructured":"Sunderk\u00f6tter C, Riemekasten G (2006) [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach]. Hautarzt 57: 819\u2013828; quiz 829","journal-title":"Hautarzt"},{"key":"282_CR5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/art.1780390717","volume":"39","author":"Freedman","year":"1996","unstructured":"Freedman RR, Mayes MD (1996) Familial aggregation of primary Raynaud\u2019s disease. Arthritis Rheum 39: 1189\u20131191","journal-title":"Arthritis Rheum"},{"key":"282_CR6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/art.20988","volume":"52","author":"Suter","year":"2005","unstructured":"Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud\u2019s phenomenon in the community. Arthritis Rheum 52: 1259\u20131263","journal-title":"Arthritis Rheum"},{"key":"282_CR7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","volume":"158","author":"Spencer-Green","year":"1998","unstructured":"Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158: 595\u2013600","journal-title":"Arch Intern Med"},{"key":"282_CR8","doi-asserted-by":"crossref","first-page":"H1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","volume":"278","author":"Chotani","year":"2000","unstructured":"Chotani MA, Flavahan S, Mitra S et al. (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278: H1075\u2013H1083","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"282_CR9","doi-asserted-by":"crossref","first-page":"H59","DOI":"10.1152\/ajpheart.00268.2003","volume":"286","author":"Chotani","year":"2004","unstructured":"Chotani MA, Mitra S, Su BY et al. (2004) Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 286: H59\u2013H67","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"282_CR10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/mol.60.6.1195","volume":"60","author":"Jeyaraj","year":"2001","unstructured":"Jeyaraj SC, Chotani MA, Mitra S et al. (2001) Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol 60: 1195\u20131200","journal-title":"Mol Pharmacol"},{"key":"282_CR11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","volume":"94","author":"Bailey","year":"2004","unstructured":"Bailey SR, Eid AH, Mitra S et al. (2004) Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 94: 1367\u20131374","journal-title":"Circ Res"},{"key":"282_CR12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/ard.55.2.122","volume":"55","author":"Herrick","year":"1996","unstructured":"Herrick AL, Illingworth K, Blann A et al. (1996) Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud\u2019s phenomenon and systemic sclerosis. Ann Rheum Dis 55: 122\u2013127","journal-title":"Ann Rheum Dis"},{"key":"282_CR13","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/art.11060","volume":"48","author":"Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Pfenninger D, Kehrer C et al. (2003) Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud\u2019s phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 48: 1992\u20132000","journal-title":"Arthritis Rheum"},{"key":"282_CR14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1365-2281.1998.00105.x","volume":"18","author":"Leppert","year":"1998","unstructured":"Leppert J, Ringqvist A, Karlberg BE, Ringqvist I (1998) Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud\u2019s phenomenon. Clin Physiol 18: 420\u2013425","journal-title":"Clin Physiol"},{"key":"282_CR15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.59.11.870","volume":"59","author":"Smythe","year":"2000","unstructured":"Smythe A, Bell A, Bruce I et al. (2000) Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud\u2019s phenomenon. Ann Rheum Dis 59: 870\u2013874","journal-title":"Ann Rheum Dis"},{"key":"282_CR16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","volume":"336","author":"Zamora","year":"1990","unstructured":"Zamora MR, O\u2019Brien RF, Rutherford RB, Weil JV (1990) Serum endothelin-1 concentrations and cold provocation in primary Raynaud\u2019s phenomenon. Lancet 336: 1144\u20131147","journal-title":"Lancet"},{"key":"282_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1523-1747.ep12360103","volume":"101","author":"Knock","year":"1993","unstructured":"Knock GA, Terenghi G, Bunker CB et al. (1993) Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud\u2019s phenomenon and systemic sclerosis. J Invest Dermatol 101: 73\u201378","journal-title":"J Invest Dermatol"},{"key":"282_CR18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.11364","volume":"50","author":"Kawaguchi","year":"2004","unstructured":"Kawaguchi Y, Takagi K, Hara M et al. (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50: 216\u2013226","journal-title":"Arthritis Rheum"},{"key":"282_CR19","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R et al. (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"282_CR20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","volume":"336","author":"Bunker","year":"1990","unstructured":"Bunker CB, Terenghi G, Springall DR et al. (1990) Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon. Lancet 336: 1530\u20131533","journal-title":"Lancet"},{"key":"282_CR21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","volume":"342","author":"Bunker","year":"1993","unstructured":"Bunker CB, Reavley C, O\u2019Shaughnessy DJ, Dowd PM (1993) Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud\u2019s phenomenon. Lancet 342: 80\u201383","journal-title":"Lancet"},{"key":"282_CR22","doi-asserted-by":"crossref","unstructured":"Herrick AL (2005) Pathogenesis of Raynaud\u2019s phenomenon. Rheumatology (Oxford) 44: 587\u2013596","DOI":"10.1093\/rheumatology\/keh552"},{"key":"282_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7326\/0003-4819-96-5-610","volume":"96","author":"Kahaleh","year":"1982","unstructured":"Kahaleh MB, Osborn I, Leroy EC (1982) Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 96: 610\u2013613","journal-title":"Ann Intern Med"},{"key":"282_CR24","first-page":"878","volume":"9","author":"Kallenberg","year":"1982","unstructured":"Kallenberg CG, Vellenga E, Wouda AA, The TH (1982) Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud\u2019s phenomenon. J Rheumatol 9: 878\u2013884","journal-title":"J Rheumatol"},{"key":"282_CR25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/bjs.1800810608","volume":"81","author":"Kent","year":"1994","unstructured":"Kent PJ, Williams GA, Kester RC (1994) Platelet activation during hand vibration. Br J Surg 81: 815\u2013818","journal-title":"Br J Surg"},{"key":"282_CR26","first-page":"99","volume":"12","author":"Seibold","year":"1985","unstructured":"Seibold JR, Harris JN (1985) Plasma beta-thromboglobulin in the differential diagnosis of Raynaud\u2019s phenomenon. J Rheumatol 12: 99\u2013103","journal-title":"J Rheumatol"},{"key":"282_CR27","first-page":"4","volume":"19","author":"Herrick","year":"2001","unstructured":"Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19: 4\u20138","journal-title":"Clin Exp Rheumatol"},{"key":"282_CR28","first-page":"1477","volume":"21","author":"Herrick","year":"1994","unstructured":"Herrick AL, Rieley F, Schofield D et al. (1994) Micronutrient antioxidant status in patients with primary Raynaud\u2019s phenomenon and systemic sclerosis. J Rheumatol 21: 1477\u20131483","journal-title":"J Rheumatol"},{"key":"282_CR29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/01.CIR.72.3.466","volume":"72","author":"Coffman","year":"1985","unstructured":"Coffman JD, Rasmussen HM (1985) Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud\u2019s phenomenon. Circulation 72: 466\u2013470","journal-title":"Circulation"},{"key":"282_CR30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/j.1552-4604.1992.tb05777.x","volume":"32","author":"Franssen","year":"1992","unstructured":"Franssen C, Wollersheim H, de Haan A, Thien T (1992) The influence of different beta-blocking drugs on the peripheral circulation in Raynaud\u2019s phenomenon and in hypertension. J Clin Pharmacol 32: 652\u2013659","journal-title":"J Clin Pharmacol"},{"key":"282_CR31","first-page":"72","volume":"13","author":"Diehm","year":"1984","unstructured":"Diehm C, Muller-Buhl U, Mechterscheimer U, Morl H (1984) [Local treatment with isosorbide dinitrate ointment in Raynaud\u2019s phenomenon]. Vasa 13: 72\u201374","journal-title":"Vasa"},{"key":"282_CR32","first-page":"50","volume":"22","author":"Whitmore","year":"1995","unstructured":"Whitmore SE, Wigley FM, Wise RA (1995) Acute effect of topical minoxidil on digital blood flow in patients with Raynaud\u2019s phenomenon. J Rheumatol 22: 50\u201354","journal-title":"J Rheumatol"},{"key":"282_CR33","doi-asserted-by":"crossref","unstructured":"Anderson ME, Moore TL, Hollis S et al. (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud\u2019s phenomenon and systemic sclerosis. Rheumatology (Oxford) 41: 324\u2013328","DOI":"10.1093\/rheumatology\/41.3.324"},{"key":"282_CR34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","volume":"1","author":"Franks","year":"1982","unstructured":"Franks AG Jr (1982) Topical glyceryl trinitrate as adjunctive treatment in Raynaud\u2019s disease. Lancet 1: 76\u201377","journal-title":"Lancet"},{"key":"282_CR35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","volume":"34","author":"Teh","year":"1995","unstructured":"Teh LS, Manning J, Moore T et al. (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud\u2019s phenomenon. Br J Rheumatol 34: 636\u2013641","journal-title":"Br J Rheumatol"},{"key":"282_CR36","doi-asserted-by":"crossref","unstructured":"Thompson AE, Pope JE (2005) Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis. Rheumatology (Oxford) 44: 145\u2013150","DOI":"10.1093\/rheumatology\/keh390"},{"key":"282_CR37","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V et al. (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 44: 1841\u20131847","journal-title":"Arthritis Rheum"},{"key":"282_CR38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00315217","volume":"40","author":"Kallenberg","year":"1991","unstructured":"Kallenberg CG, Wouda AA, Meems L, Wesseling H (1991) Once daily felodipine in patients with primary Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 40: 313\u2013315","journal-title":"Eur J Clin Pharmacol"},{"key":"282_CR39","first-page":"524","volume":"32","author":"La","year":"1993","unstructured":"La Civita L, Pitaro N, Rossi M et al. (1993) Amlodipine in the treatment of Raynaud\u2019s phenomenon. Br J Rheumatol 32: 524\u2013525","journal-title":"Br J Rheumatol"},{"key":"282_CR40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00558230","volume":"37","author":"Schmidt","year":"1989","unstructured":"Schmidt JF, Valentin N, Nielsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 37: 191\u2013192","journal-title":"Eur J Clin Pharmacol"},{"key":"282_CR41","first-page":"858","volume":"14","author":"da","year":"1987","unstructured":"da Costa J, Gomes JA, Espirito Santo J, Queiros M (1987) Inefficacy of diltiazem in the treatment of Raynaud\u2019s phenomenon with associated connective tissue disease: a double blind placebo controlled study. J Rheumatol 14: 858\u2013859","journal-title":"J Rheumatol"},{"key":"282_CR42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.44.1.30","volume":"44","author":"Kahan","year":"1985","unstructured":"Kahan A, Amor B, Menkes CJ (1985) A randomized double-blind trial of diltiazem in the treatment of Raynaud\u2019s phenomenon. Ann Rheum Dis 44: 30\u201333","journal-title":"Ann Rheum Dis"},{"key":"282_CR43","first-page":"724","volume":"12","author":"Rhedda","year":"1985","unstructured":"Rhedda A, McCans J, Willan AR, Ford PM (1985) A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud\u2019s phenomenon. J Rheumatol 12: 724\u2013727","journal-title":"J Rheumatol"},{"key":"282_CR44","doi-asserted-by":"crossref","unstructured":"Coleiro B, Marshall SE, Denton CP et al. (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40: 1038\u20131043","DOI":"10.1093\/rheumatology\/40.9.1038"},{"key":"282_CR45","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev CD\u00a0000954"},{"key":"282_CR46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","volume":"13","author":"Janini","year":"1988","unstructured":"Janini SD, Scott DG, Coppock JS et al. (1988) Enalapril in Raynaud\u2019s phenomenon. J Clin Pharm Ther 13: 145\u2013150","journal-title":"J Clin Pharm Ther"},{"key":"282_CR47","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2)\u00a0CD\u00a0000953"},{"key":"282_CR48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","volume":"347","author":"Wigley","year":"2002","unstructured":"Wigley FM (2002) Clinical practice. Raynaud\u2019s Phenomenon. N Engl J Med 347: 1001\u20131008","journal-title":"N Engl J Med"},{"key":"282_CR49","first-page":"1407","volume":"19","author":"Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA et al. (1992) Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19: 1407\u20131414","journal-title":"J Rheumatol"},{"key":"282_CR50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s003930050070","volume":"57","author":"Riemekasten","year":"1998","unstructured":"Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) [Iloprost administration over 21 days as an effective therapy in systemic scleroderma \u2013 case report and review of the literature]. Z Rheumatol 57: 118\u2013124","journal-title":"Z Rheumatol"},{"key":"282_CR51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","volume":"54","author":"Belch","year":"1995","unstructured":"Belch JJ, Capell HA, Cooke ED et al. (1995) Oral iloprost as a treatment for Raynaud\u2019s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54: 197\u2013200","journal-title":"Ann Rheum Dis"},{"key":"282_CR52","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME et al. (1998) Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41: 670\u2013677","journal-title":"Arthritis Rheum"},{"key":"282_CR53","first-page":"137","volume":"47","author":"Bartolone","year":"1999","unstructured":"Bartolone S, Trifiletti A, De Nuzzo G et al. (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud\u2019s phenomenon. Minerva Cardioangiol 47: 137\u2013143","journal-title":"Minerva Cardioangiol"},{"key":"282_CR54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/03009740310004711","volume":"33","author":"Marasini","year":"2004","unstructured":"Marasini B, Massarotti M, Bottasso B et al. (2004) Comparison between iloprost and alprostadil in the treatment of Raynaud\u2019s phenomenon. Scand J Rheumatol 33: 253\u2013256","journal-title":"Scand J Rheumatol"},{"key":"282_CR55","first-page":"77","volume":"197","author":"Varela-Aguilar","year":"1997","unstructured":"Varela-Aguilar JM, Sanchez-Roman J, Talegon Melendez A, Castillo Palma MJ (1997) [Comparative study of misoprostol and nifedipine in the treatment of Raynaud\u2019s phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex]. Rev Clin Esp 197: 77\u201383","journal-title":"Rev Clin Esp"},{"key":"282_CR56","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2004.034488","volume":"64","author":"Gore","year":"2005","unstructured":"Gore J, Silver R (2005) Oral sildenafil for the treatment of Raynaud\u2019s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64: 1387","journal-title":"Ann Rheum Dis"},{"key":"282_CR57","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/ard.2003.015677","volume":"63","author":"Kumana","year":"2004","unstructured":"Kumana CR, Cheung GT, Lau CS (2004) Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 63: 1522\u20131524","journal-title":"Ann Rheum Dis"},{"key":"282_CR58","first-page":"1918","volume":"33","author":"Kumar","year":"2006","unstructured":"Kumar N, Griffiths B, Allen J (2006) Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud\u2019s phenomenon in patients with systemic sclerosis: a potential treatment. J Rheumatol 33: 1918\u20131919","journal-title":"J Rheumatol"},{"key":"282_CR59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-139-10-200311180-00030","volume":"139","author":"Rosenkranz","year":"2003","unstructured":"Rosenkranz S, Diet F, Karasch T et al. (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann Intern Med 139: 871\u2013873","journal-title":"Ann Intern Med"},{"key":"282_CR60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","volume":"166","author":"Caglayan","year":"2006","unstructured":"Caglayan E, Huntgeburth M, Karasch T et al. (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166: 231\u2013233","journal-title":"Arch Intern Med"},{"key":"282_CR61","first-page":"CD","volume":"Rev","author":"Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A et al. (2000) Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2): CD\u00a0000956","journal-title":"Cochrane Database Syst"},{"key":"282_CR62","first-page":"71","volume":"18","author":"van","year":"1987","unstructured":"van der Meer J, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud\u2019s phenomenon. Vasa Suppl 18: 71\u201375","journal-title":"Vasa Suppl"},{"key":"282_CR63","first-page":"499","volume":"18","author":"Denton","year":"2000","unstructured":"Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud\u2019s phenomenon: a pilot study. Clin Exp Rheumatol 18: 499\u2013502","journal-title":"Clin Exp Rheumatol"},{"key":"282_CR64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/1358863x02vm455oa","volume":"7","author":"Muir","year":"2002","unstructured":"Muir AH, Robb R, McLaren M et al. (2002) The use of Ginkgo biloba in Raynaud\u2019s disease: a double-blind placebo-controlled trial. Vasc Med 7: 265\u2013267","journal-title":"Vasc Med"},{"key":"282_CR65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/art.1780290822","volume":"29","author":"Goldberg","year":"1986","unstructured":"Goldberg J, Dlesk A (1986) Successful treatment of Raynaud\u2019s phenomenon with pentoxifylline. Arthritis Rheum 29: 1055\u20131056","journal-title":"Arthritis Rheum"},{"key":"282_CR66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/000331978703800801","volume":"38","author":"Neirotti","year":"1987","unstructured":"Neirotti M, Longo F, Molaschi M et al. (1987) Functional vascular disorders: treatment with pentoxifylline. Angiology 38: 575\u2013580","journal-title":"Angiology"},{"key":"282_CR67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0950-821X(88)80070-7","volume":"2","author":"de","year":"1988","unstructured":"de Trafford JC, Lafferty K, Potter CE et al. (1988) An epidemiological survey of Raynaud\u2019s phenomenon. Eur J Vasc Surg 2: 167\u2013170","journal-title":"Eur J Vasc Surg"},{"key":"282_CR68","doi-asserted-by":"crossref","unstructured":"Flatt AE (1980) Digital artery sympathectomy. J Hand Surg [Am] 5: 550\u2013556","DOI":"10.1016\/S0363-5023(80)80104-3"},{"key":"282_CR69","doi-asserted-by":"crossref","unstructured":"Ruch DS, Holden M, Smith BP et al. (2002) Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up. J Hand Surg [Am] 27: 258\u2013264","DOI":"10.1053\/jhsu.2002.29483"},{"key":"282_CR70","first-page":"61","volume":"66","author":"Albrecht","year":"2007","unstructured":"Albrecht K, M\u00fcller-Eschner M, Saar P et al. (2007) Evaluation des Therapieeffekts kohlens\u00e4urehaltiger Handb\u00e4der auf die akrale Durchblutung bei Patienten mit systemischer Sklerose mittels Dopplersonographie. Z Rheumatol 66 (Suppl 1): 61","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-008-0282-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0282-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:35:55Z","timestamp":1559061355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-008-0282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,25]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s00393-008-0282-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,25]]}}}